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ABSTRACT
Glucocorticoids are widely used to treat inflammatory disorders; however, prolonged use of glucocorti-
coids results in side effects including osteoporosis, diabetes and obesity. Compound A (CpdA), identified
as a selective NR3C1/glucocorticoid receptor (nuclear receptor subfamily 3, group C, member 1)
modulator, exhibits an inflammation-suppressive effect, largely in the absence of detrimental side
effects. To understand the mechanistic differences between the classic glucocorticoid dexamethasone
(DEX) and CpdA, we looked for proteins oppositely regulated in bone marrow-derived macrophages
using an unbiased proteomics approach. We found that the autophagy receptor SQSTM1 but not
NR3C1 mediates the anti-inflammatory action of CpdA. CpdA drives SQSTM1 upregulation by recruiting
the NFE2L2 transcription factor to its promoter. In contrast, the classic NR3C1 ligand dexamethasone
recruits NR3C1 to the Sqstm1 promoter and other NFE2L2-controlled gene promoters, resulting in gene
downregulation. Both DEX and CpdA induce autophagy, with marked different autophagy character-
istics and morphology. Suppression of LPS-induced Il6 and Ccl2 genes by CpdA in macrophages is
hampered upon Sqstm1 silencing, confirming that SQSTM1 is essential for the anti-inflammatory
capacity of CpdA, at least in this cell type. Together, these results demonstrate how off-target mechan-
isms of selective NR3C1 ligands may contribute to a more efficient anti-inflammatory therapy.
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Glucocorticoids (GCs) are widely used to treat different
inflammatory diseases including rheumatoid arthritis and
asthma [1–3]. The natural (cortisol) and synthetic (e.g., dex-
amethasone) glucocorticoids are known ligands of NR3C1/
glucocorticoid receptor (nuclear receptor subfamily 3, group
C, member 1). These glucocorticoids bind NR3C1 in the
cytoplasm leading to its translocation to the nucleus where
it functions as a transcription factor. Activated NR3C1 can
upregulate the transcription of different genes involved in
metabolism such as PCK1, TAT, G6PC and some anti-inflam-
matory genes such as TSC22D3/GILZ and DUSP1 by binding
to NR3C1 response elements (GRE), a process known as
transactivation [4,5]. Also, NR3C1 can transrepress pro-
inflammatory genes such as IL6, CCL2, and TNF via tethering
to NFKB and AP-1 (FOS/JUN) complexes, or via direct bind-
ing to negative GREs [6,7].
GCs remain the most common prescribed anti-inflammatory
drugs despite their possible severe side effects. Prolonged
systemic treatment with GCs is associated with acquired resis-
tance to treatment, hypertension, osteoporosis and increased
glucose levels leading to diabetes. Selective NR3C1 modulators
are studied as potential tools to solve this problem [8]. Using in
vitro and in vivo models, the dissociative nonsteroidal selective
NR3C1 modulator compound A (CpdA) was shown to exhibit
an inflammation-suppressive effect, largely in the absence of the
aforementioned side effects [9–13]. CpdA is a synthetic analog of
the plant-derived hydroxy phenyl aziridine precursor [14].
Recently, it was reported that CpdA can target the NFKB path-
way via a NR3C1-independent mechanism [13,15]. However,
how a CpdA-mediated NR3C1-independent mechanism may
work and which proteins are necessary for the anti-inflamma-
tory action of CpdA remain largely unknown.
NFE2L2 (nuclear factor, erythroid derived 2, like 2) is a tran-
scription factor responsible for the regulation of cellular redox
balances and for the protective antioxidant and phase II detoxifi-
cation response [16,17]. NFE2L2 is tethered to KEAP1, which is
highly enriched in cysteine residues and gets continuously ubiqui-
tinated and degraded by the proteasome. Upon oxidative stress or
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treatment with NFE2L2 inducers, NFE2L2 escapes from KEAP1
retention and translocates to the nucleus where it heterodimerizes
with small MAF proteins to transactivate genes with antioxidant
response elements (AREs) in their promoters, such as HMOX1,
NQO1 and TXNRD1. Autophagy receptors SQSTM1 and
CALCOCO2/NDP52 also have AREs in their promoters and can
be regulated byNFE2L2 [17,18].Moreover, SQSTM1 can act as an
activator of NFE2L2 via the inactivation of KEAP1 [19,20]. As an
autophagy receptor, SQSTM1 binds to ubiquitinated cargo sub-
strates and, by interaction with the phagophore-bound
MAP1LC3/LC3 protein, targets them for degradation in a process
known as autophagy [21,22].
The search for factors that underlie the anti-inflammatory
properties of CpdA will not only help to clarify the debated
NR3C1 transrepression/transactivation paradigm [23], but might
also contribute to the discovery of alternative and safer anti-
inflammatory drugs. By using a shotgun mass spectrometry ana-
lysis, we identified SQSTM1 andHMOX1 as significantly upregu-
lated proteins following CpdA treatment ofmurine bonemarrow-
derived macrophages (BMDMs) under inflamed cellular condi-
tions (LPS). We hypothesized that SQSTM1 and/or other mem-
bers of an NFE2L2-dependent pathway might be involved in
NR3C1-independentCpdA-induced suppression of inflammation
in macrophages. Although SQSTM1 was shown to be involved in
the regulation of inflammation in macrophages [24], very little is
knownabout the transcriptional regulation of SQSTM1byNR3C1
ligands andmodulators, and how this can affect gene transcription
of inflammatory markers.
Here, we show that the selective NR3C1 modulator CpdA
upregulates, while dexamethasone (DEX) downregulates,
SQSTM1, HMOX1 and TXNRD1 in BMDM via different
mechanisms at the level of gene transcription. CpdA recruits
NFE2L2, while DEX recruits NR3C1 to the promoters of the
Sqstm1, Hmox1 and Il6 genes. CpdA-mediated suppression of
LPS-induced Il6 and Ccl2 in BMDM appeared to be NR3C1
independent and was hampered only upon silencing of Sqstm1.
Remarkably, regardless of the opposite regulation of SQSTM1,
both DEX and CpdA are able to ultimately induce autophagy in
BMDM, suggesting that a staged uncoupling between SQSTM1
regulation and autophagy is possible.
Results
SQSTM1 is identified as a protein that behaves in an
opposite manner following CpdA versus DEX treatment in
LPS-induced macrophages
Because of the very different chemical structures between
dexamethasone (DEX) and CpdA (Fig. S1A), we reasoned
that the action mechanism of CpdA might also involve
other target proteins besides NR3C1, and we were specifically
interested in those proteins differentially regulated by CpdA
compared to DEX in an inflammatory context. To find this
differential protein profile, we compared combinations of
CpdA and LPS versus LPS alone, and of DEX and LPS versus
LPS alone using mass spectrometry-based shotgun proteomics
in BMDMs (Figure 1A). These cells serve as a good model for
inflammation-related studies because they are key compo-
nents of the innate immune system [25]. The higher dose of
CpdA (10 μM) compared to DEX (1 μM) is in accord with the
effective in vitro anti-inflammatory dose of this nonsteroidal
compound, as established previously [14].
As a validation of the inflammatory stimuli and the accuracy
of this method, many classic inflammatory proteins, including
among others IL1B, NOS2, ICAM1, and NFKB2 were found to
be significantly upregulated in LPS-treated cells compared to
solvent (non-induced [NI]) (Fig. S1B). In total, over 2,760 pro-
teins were quantified by shotgun proteomics, and a statistical
analysis comparing cells treated with CpdA + LPS versus LPS
alone revealed 4 significantly (p < 0.01) upregulated and 12
significantly downregulated proteins (Figure 1B). Ingenuity
Pathway Analysis (IPA®) of these 16 proteins assigned 13 hereof
to the ‘Infectious Diseases, Cell-To-Cell Signaling and
Interaction, Hematological Disease’ network (Figure 1C).
Among these proteins, SQSTM1 and HMOX1 caught our atten-
tion because of a common transcription regulator, NFE2L2 [26].
Because these proteins were not upregulated in the DEX+ LPS vs
LPS set-up (Figure 1D), we considered them as potential candi-
dates to explain the ability of CpdA to suppress inflammation,
possibly independently from NR3C1, in a LPS-induced BMDM
model. SQSTM1 was rather downregulated (p = 0.006 and 0.59-
fold change) in the DEX + LPS vs LPS set-up (Figure 1D). DEX-
regulated proteins in the inflamed macrophages were also
assigned by IPA to an inflammation-related network (Figure 1E).
In support, SQSTM1 was detected by mass spectrometry ana-
lysis also in human lung epithelial A549 cells as a differentially
regulated protein, when comparing CpdA versus DEX treatment
in combination with TNF as an alternative inflammatory stimulus
(Fig. S2C, S2D).
DEX and CpdA differentially regulate NFE2L2-dependent
genes in murine and human macrophages
To validate the mass spectrometry results and reveal further
mechanistic details of regulation, we compared the effect of DEX
versus CpdA on the regulation of Sqstm1, and by extension of
other typical NFE2L2-dependent genes, Hmox1 and Txnrd1, in
primaryBMDMs.Hereto,wemeasuredmRNAexpression after 6-
h treatment with DEX or CpdA in the absence or presence of LPS.
DEX mostly suppressed these genes, while CpdA upregulated
them (more than 2 fold). This regulation was largely similar in
the presence of LPS (Figure 2A). The regulation of HMOX1 at the
protein level followed the pattern ofmRNAregulation (Figure 2B).
The observed Sqstm1 upregulation by CpdA at the mRNA level
was much stronger than at the protein level, whereas the DEX-
induced suppression of the SQSTM1 protein was much more
prominent in comparison to the observed decrease in Sqstm1
mRNA. LPS treatment by itself upregulated both SQSTM1 and
HMOX1 (Figure 2B). As a positive control, treatment with the
NFE2L2 activator sulforaphane resulted in an increase of the
Sqstm1 gene expression level comparable to the level obtained
with CpdA. Sulforaphane did lead to a much stronger upregula-
tion of HMOX1 both at the mRNA and protein level (Fig. S3A,
S3B). As expected from an NR3C1-activating steroid, the DEX-
induced downregulation of Sqstm1 was completely abolished
upon Nr3c1 silencing (Figure 2C). To our surprise, the CpdA-
activated gene expression of Sqstm1 was largely retained upon
silencing of Nr3c1, indicating a role for another transcriptional
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Figure 1. LC-MS/MS analysis reveals differentially expressed proteins in BMD macrophages treated with DEX or CpdA under the inflammatory condition. (A)
Schematic overview of the mass spectrometry-based shotgun proteomics experiment. (B) Volcano plot with significantly up- (red) or downregulated (green) proteins
in CpdA + LPS versus LPS alone. CpdA (10 μM) and 100 ng/ml LPS treatments were used. Statistics by multiple two-sample t-tests, each with a permutation-based
FDR of 0.05 and S0 value of 0.1 for truncation. (N = 3). (C) Ingenuity pathway analysis (www.qiagenbioinformatics.com) of significantly regulated proteins from CpdA
+ LPS versus LPS comparison. (D) Volcano plot with significantly up- (red) or downregulated (green) proteins in DEX + LPS versus LPS. DEX (1 μM) and 100 ng/ml LPS
treatments were used. Statistics by multiple two-sample t-tests, each with a permutation-based FDR of 0.05 and S0 value of 0.1 for truncation. (N = 3). (E) Ingenuity
pathway analysis of significantly regulated proteins from DEX+ LPS versus LPS comparison.
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regulator. UponNfe2l2 silencing, the potential of DEX to mediate
Sqstm1 gene downregulation was unaffected, whereas the capacity
of CpdA to upregulate Sqstm1 was strongly attenuated
(Figure 2C). The efficiency of Nr3c1 and Nfe2l2 silencing is
depicted in Figure S3C.
To evaluate the significance of novel mRNA synthesis to
potentially explain the above-described differential gene reg-
ulation, we co-treated BMDM with the transcription inhibitor
actinomycin D (ActD) and measured Sqstm1 and Hmox1
mRNA levels. Figure 2D shows that both for Sqstm1 and
Figure 2. CpdA induces while DEX suppresses a subset of NRF2-dependent genes in macrophages. (A) qPCR analysis of BMDMs treated with vehicle, 1 μM DEX, 10
μM CpdA and 100 ng/ml LPS for 6 h. Gene expression levels were normalized to Ppia/cyclophilin and Rn18s using qbase+ . Statistical analysis was done using two-
way ANOVA and Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 4). NI, non-induced. (B) Immunoblotting of BMDMs treated with 1 μM DEX,
10 μM CpdA and 100 ng/ml LPS for 6 h. Densitometry was done using ImageJ. The SQSTM1 signal is normalized to ACTA1/actin. kDa, kilodaltons. (C) qPCR analysis of
BMDMs treated with 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS for 6 h after Nr3c1 and Nfe2l2 were knocked down for 50 h. Statistics by two-way ANOVA and
Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 4, bars represent mean+ SEM). (D) qPCR analysis of BMDMs treated with 1 μM DEX, 10 μM
CpdA and 10 μg/ml of the transcriptional inhibitor actinomycin D for 6 h. Statistics by two-way ANOVA and Dunnett’s test (**p < 0.01, ****p < 0.0001, N = 4). (E)
Representative NFE2L2 (green) and NR3C1 (red) staining in BMDM cells after 1 h treatment with vehicle, 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS (scale bar: 10 μm)
.
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Hmox1, de novo mRNA synthesis was required to maintain
mRNA levels under solvent only-treated conditions. In the
presence of ActD, no additional changes in the amount of
mRNA across treatments were observed, suggesting at least
for CpdA the need for gene transcription and de novo mRNA
synthesis to mediate the increase in Sqstm1 and Hmox1
mRNA levels (Figure 2D).
Using indirect immunofluorescence, we determined the
subcellular localization of NR3C1 and NFE2L2 in response
to CpdA and DEX treatment in BMDM. Only DEX induced
complete nuclear accumulation of NR3C1 to the nucleus.
DEX or CpdA treatment left the subcellular localization of
NFE2L2 largely unhampered (Figure 2E). However, both
CpdA and DEX did counteract the LPS-induced nuclear
accumulation of NFE2L2 (Figure 2E).
We next asked whether the regulation by DEX and CpdA
of Sqstm1 and typical NFE2L2-dependent genes would be
similar for human macrophages. CpdA upregulated mRNA
levels of SQSTM1, HMOX1, TXNRD1and NQO1 at least 2 fold
in human THP-1 macrophages following a 6-h treatment
under normal and inflammatory conditions. Again, DEX
mainly decreased mRNA levels of these genes (Fig. S3E).
Together these findings suggest that in BMDM, DEX sup-
presses a subset of NFE2L2-dependent genes via a transcriptional
mechanism in an NR3C1-dependent manner, while CpdA
induces the same genes at least partially via anNFE2L2-dependent
mechanism.
Glucocorticoids recruit NR3C1, whereas CpdA recruits
NFE2L2 to the Sqstm1, Il6 and Il1b promoters in
macrophages
To understand the mechanism behind the differential tran-
scriptional regulation of Sqstm1 in response to classic GCs
versus CpdA, we performed NR3C1, NFE2L2 and JUNB
chromatin immunoprecipitation (ChIP) with subsequent
qPCR analysis of the Sqstm1 promoter region in macro-
phages. Sqstm1 was recently shown to be a direct target of
the transcription factor JUNB [27]. Treatment with DEX
resulted in NR3C1 recruitment concomitant with a partial
release of NFE2L2 and JUNB from the Sqstm1 promoter in
BMDM (Figure 3A, left panel). CpdA treatment did not
recruit NR3C1, but substantially increased NFE2L2 binding
(Figure 3A, left panel). As with DEX, CpdA also caused a
partial release of JUNB binding. Taking into account a large
divergence of NR3C1 binding events between human and
murine macrophages [28], to observe a quite similar above-
described regulation at SQSTM1 and HMOX1 promoters also
in human THP-1 macrophages is suggestive of conserved TF
binding mechanisms (Fig. S4A, S4B). CpdA treatment
resulted in increased occupancy of phospho-Ser2 POLR2/
RNA polymerase II (p-POLR2) at SQSTM1 and HMOX1
genes in these cells, in line with increased transcriptional
activity. In contrast, DEX treatment rather exhibited
decreased p-POLR2 binding to these genes (Fig. S4C). In
support of these findings, in silico analysis of human and
murine TF binding sites present in ChIP-qPCR fragments,
by using the JASPAR database, revealed strong and highly
conserved JUNB- and NFE2L2-binding motifs both in human
and murine Sqstm1 promoters (Figure 3B). Interestingly, the
NFE2L2 motif resembles the JUNB motif, extended with 4
base pairs. Despite the presence of a NR3C1/GR binding event
to the promoter region, the GRE motif was not retrieved,
suggesting the possibility of a NR3C1 tethering mechanism.
Strikingly, the above described transcription factor binding
profile of NR3C1, NFE2L2 and JUNB at the Sqstm1 promoter
in BMDMs remains the same even upon triggering inflamma-
tion with LPS (Figure 3A, right panel). Even more, the bind-
ing profiles are very similar at the promoters of the 2 studied
inflammatory genes, Il6 and Il1b, with DEX treatment leading
to NR3C1 recruitment and CpdA leading to NFE2L2 recruit-
ment (Figure 3C). Both compounds behave similarly in terms
of a decreased binding of JUNB. Despite the similar pattern of
NFE2L2 recruitment upon CpdA treatment, the transcrip-
tional output is different: at the Sqstm1 promoter this recruit-
ment results in the induction of mRNA, whereas at Il6 and
Il1b promoters it leads to the suppression of mRNA transcrip-
tion (Figure 3D).
Taken together, DEX and CpdA recruit NR3C1 and
NFE2L2 respectively, to the Sqstm1, Il6 and Il1b promoters,
there replacing JUNB. These transcriptional events result in
the suppression of Il6 and Il1b by both compounds, but lead
to the induction of Sqstm1 upon CpdA, or its suppression
upon DEX, treatment.
Both DEX and CpdA induce autophagy in BMDMs
Because the main known role of SQSTM1 in cells is its
involvement in autophagy as a cargo receptor, we studied
the regulation of autophagy by DEX and CpdA in macro-
phages. First, we determined mRNA expression of different
autophagy-related genes (Figure 4A). Becn1 and Atg10 were
not regulated by any treatment. According to the mass spec-
trometry analysis, the ATG5 protein was significantly sup-
pressed by DEX in the non-LPS condition (Fig. S2A). This
was confirmed both at the mRNA level (Figure 4A) and
protein level (Figure 4B lane 5). Strikingly, at the protein
but not at the mRNA level (Figure 4A) CpdA treatment
decreased ATG5 in basal and inflamed conditions
(Figure 4B, lane 6 and 9 vs lane 4). Map1lc3b mRNA was
modestly upregulated by both DEX and CpdA treatments
(Figure 4A). Intriguingly, LPS treatment suppressed overall
mRNA levels of Map1lc3b and Atg7, regardless of additional
treatments. LPS enhanced mRNA levels of the mitophagy
receptor Optn [29], whereas DEX and CpdA both suppressed
this enhancement back to basal levels (Figure 4A).
Western blot analysis demonstrated that already upon
15 min of CpdA administration combined with LPS, the levels
of the lipidated form of MAP1LC3A/B (LC3A/B-II) were
increased (Figure 4C, lane 3 versus 1). Depletion of the
cytoplasmic form of LC3A/B (LC3A/B-I) was observed after
1 h and 2 h treatment (Figure 4C, lanes 6 and 9) leading to the
decrease of both LC3A/B bands at 6 h (Figure 4C, lane 12).
Ubiquitination of all proteins and depletion of monoubiquitin
was further apparent at 2 h of CpdA plus LPS treatment
(Figure 4B, lane 3), followed by depletion of ubiquitinated
proteins at 6 h (Figure 4B, lane 9). SQSTM1 protein upregu-
lation by CpdA with LPS was less prominent as compared to
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the fold changes detected at the mRNA level (Figure 2A)
possibly because of an additional elimination process by
ongoing autophagy (Figure 4B, lane 9). In line herewith,
immunofluorescence analysis revealed that LPS enhanced
formation of SQSTM1-associated puncta, which were even
more pronounced upon adding CpdA (Figure 4D). DEX
treatment combined with LPS was also consistent with an
autophagy-supporting pattern (Figure 4C, lane 8) at 2 h. At
Figure 3. DEX recruits NR3C1 whereas CpdA recruits NFE2L2 to Sqstm1, Il6 and Il1b promoters. BMDMs were treated with vehicle, 1 μM DEX, 10 μM CpdA and
100 ng/ml LPS for 1 h. Recruitment of NR3C1, JUNB and NFE2L2 to (A) Sqstm1 or (C) Il6 and Il1b promoters was measured using qPCR after immunoprecipitation with
the respective antibodies. Normal rabbit IgG (pool of chromatin from NI, DEX and CpdA treatments) served as a negative control. Statistical analysis was done using
two-way ANOVA and Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 3 or 4, bars represent mean+ SEM). NI, non-induced. (B) in silico analysis
of murine and human Sqstm1 promoter binding sites from ChIP-qPCR using JASPAR database (jaspar.genereg.net). (D) qPCR analysis of BMDMs treated with vehicle,
1 μM DEX, 10 μM CpdA and 100 ng/ml LPS for 6 h. Gene expression levels were normalized to Ppia/cyclophilin and Gapdh using qbase+ . Statistical analysis was done
using one-way ANOVA and Dunnett’s test (**p < 0.01, ***p < 0.001, ****p < 0.0001, N = 5) .
2054 V. MYLKA ET AL.
6 h of DEX treatment, a depletion of LC3A/B was clearly
observed, yet only in the absence of LPS (Figure 4B, lane 5
and lane 8).
Ultrastructural investigation of BMDM by transmission
electron microscopy (TEM) revealed autophagic phenotypes
[30] upon 2-h DEX treatment, characterized by the presence
Figure 4. DEX and CpdA induce autophagy in macrophages. (A) qPCR analysis of BMDM treated with vehicle, 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS for 6 h.
Gene expression levels were normalized to Ppia/cyclophilin and Gapdh using qbase+ . Statistical analysis was done using two-way ANOVA and Dunnett’s test
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 4). NI, non-induced. (B, C) Immunoblotting of BMDM treated with 1 μM DEX, 10 μM CpdA and 100 ng/ml
LPS for 15 min, 1 h, 2 h and 6 h. ACTA1/actin served as a loading control. kDa, kilodaltons. (D) Representative SQSTM1 (red) imaging in BMDM cells after 6-h
treatment with vehicle, 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS (scale bar: 10 μm). (E) Ultrastructural investigation of BMDM by TEM after 2-h treatment with 1 μM
DEX, 10 μM CpdA and 100 ng/ml LPS. Autophagic phenotypes upon DEX treatment were characterized by the presence of myelin-like structures and autophago-
somes. Autophagic phenotypes upon CpdA treatment were characterized by a strong vacuolization and presence of autophagosomes. V, vacuoles; MLS, myelin-like
structures; AP, autophagosomes. (F) qPCR analysis of BMDMs treated with 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS for 6 h after Sqstm1 was knocked down for
50 h. Statistical analysis was done using two-way ANOVA and Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 6). .
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of myelin-like structures and autophagosomes (Figure 4E,
upper panels). Autophagic subcellular phenotypes upon 2-h
CpdA treatment were rather characterized by a strong vacuo-
lization additional to the presence of autophagosomes.
Adding LPS led to a strong increase in the amount of mye-
lin-like structures, but was less prominent when combined
with CpdA (Figure 4E, lower panels). Strikingly, in human
THP-1 macrophages we failed to consistently pick up autop-
hagy induction by CpdA, in contrast to DEX treatment, which
was able to induce autophagy (Fig. S5, S6). One explanation
may be that for THP-1 differentiation PMA was used, which
is a known regulator of autophagy [31] that might thus inter-
fere with the regulation of particular compound-induced
autophagy processes in our experimental conditions.
In conclusion, we showed that DEX and CpdA induce
autophagy in both basal and LPS-treated BMDMs.
Knockdown of SQSTM1 selectively enhances the
expression of LPS-stimulated autophagy receptors in
BMDM
As shown above, DEX induces autophagy (Figure 4B, 4C, 4E)
while decreasing the autophagy receptors Sqstm1 and Optn at
the transcriptional level, in the presence of LPS (Fig. 2A, 4A).
This led us to hypothesize that a conserved mechanism of
maintaining autophagy receptor balance might exist. To com-
pare the impact of DEX-downregulated versus CpdA-induced
SQSTM1 protein levels on the autophagy receptor balance in
inflamed macrophages, the effect of CpdA or DEX on the
expression of other autophagy receptors was studied following
Sqstm1 knockdown.
Figure 4F demonstrates that knockdown of SQSTM1 in
LPS-treated BMDM increased mRNA levels of the Nbr1 and
Calcoco2/Ndp52 genes, but not of Optn. In analogy with the
findings for Sqstm1 (Figure 2A), addition of CpdA, but not of
DEX coincided with a further enhancement of Nbr1 and
Calcoco2/Ndp52 autophagy receptor mRNA levels in LPS-
induced BMDM, but not of Optn, which was rather sup-
pressed by both compounds (Figure 4F). This result may
point to a conserved but selective compensatory mechanism
of autophagy receptor expression upon loss of SQSTM1 and
emphasizes the ability of CpdA to stimulate, and DEX to
downregulate, expression of particular autophagy receptors
during LPS-triggered inflammation in BMDMs.
SQSTM1 is involved in CpdA-induced suppression of
inflammation in macrophages
Anti-inflammatory properties of CpdA have extensively been
demonstrated in in vitro and in vivo experiments, and CpdA
has been shown to target NFKB, in analogy to GCs [9–13].
Because CpdA did not support NR3C1 translocation to the
nuclei of BMDMs to the same extent as DEX, we wondered
what potential alternative mechanism might be involved in the
CpdA-mediated suppression of inflammation in BMDMs.
Inhibition of the late stage of autophagy by chloroquine (CQ),
i.e. inhibition of autolysosome degradation, did not impair the
ability of DEX or CpdA to suppress these LPS-induced inflam-
matory markers (Figure 5A). Interestingly, CQ pretreatment
rather increased overall CCL2 but decreased overall IL6 protein
levels in the medium of BMDM cells, suggestive of an activating
or inhibitory step of CQ on CCL2 or IL6 secretion, respectively.
Besides GR-mediated transrepression, also GR-mediated
transactivation can contribute to resolve inflammatory pro-
cesses. Hence, we measured the levels of typical GC-induced
and trans-activated genes with anti-inflammatory properties,
i.e. Tsc22d3 and Dusp1 [32,33]. Combinations with DEX, as
expected, yielded the stronger response (Figure 5B). Dusp1
mRNA was enhanced with LPS (Figure 5B), in line with ear-
lier described effects of pro-inflammatory stimuli on Dusp1
gene transcription [34]. DEX-induced Tsc22d3 levels on the
other hand, were suppressed by LPS (Figure 5B), an effect
described before by the pro-inflammatory stimulus TNF as
part of a glucocorticoid-resistance mechanism [35]. Next, we
determined to what extent DEX or CpdA was able to inhibit
LPS-induced activated p-MAPK/ERK and p-MAPK/p38, as
parts of upstream inflammatory signaling pathways (control
of LPS-induced phosphorylation depicted in Figure S7C).
Both DEX and CpdA were able to dephosphorylate LPS-
activated MAPK/ERK but not MAPK/p38 (Figure 5C). In
some cell types, induction of the NFKBIA/IκBα protein, the
inhibitor of NFKB, was described as a potential anti-inflam-
matory mechanism of DEX [36]. In the absence and presence
of LPS, only DEX, but not CpdA, showed a slight upregula-
tion of NFKBIA at 6 h (Figure 5D).
We wondered whether the possible cyclic events of a
SQSTM1 up- or downregulation could contribute or not to
the anti-inflammatory effects of CpdA as compared to DEX.
Hence, we studied to what extent SQSTM1, NR3C1 and
HMOX1 are involved in either DEX- or CpdA-induced
repression of inflammatory gene expression, using siRNA
silencing. As expected, Nr3c1 silencing diminished the anti-
inflammatory properties of DEX. In contrast to earlier find-
ings in A549 cells [37], but in line with data in dendritic cells
[15], NR3C1 silencing did not affect the ability of CpdA to
suppress Il6 and Ccl2 mRNA. In contrast, Sqstm1 silencing
did impair the ability of CpdA to suppress LPS-induced Il6
and Ccl2 in BMDMs (Figure 5E). Knockdown of Hmox1
affected neither DEX- nor CpdA-induced suppression of
inflammatory marker expression in BMDMs (Fig. S7D).
In summary, DEX-triggered suppression of LPS-induced
inflammation in BMDMs was disrupted upon silencing of
Nr3c1, while the anti-inflammatory abilities of CpdA were
substantially ablated only when Sqstm1 was silenced.
CpdA induces a subset of stress response genes in vivo
To verify whether CpdA and DEX regulate mRNA expression
in macrophages similarly in vivo as in vitro, mice were
injected intraperitoneally (i.p.) with vehicle, DEX or CpdA
in combination with LPS for 6 h. Peritoneal macrophages
were isolated and sorted via FACS, followed by mRNA isola-
tion. Upregulation of Hsp1a1 mRNA served as a positive
control for CpdA [38] (Figure 6). Just as in primary
BMDMs, also in peritoneal macrophages DEX, but not
CpdA, enhanced the anti-inflammatory gene Tsc22d3. In con-
trast to the basal condition, in which both compounds
increased Map1lc3b mRNA (Fig. S8), in LPS-treated mice
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only CpdA upregulated this gene. In vivo CpdA treatment
induced, whereas DEX treatment decreased, levels of Sqstm1
and Hmox1 genes, completely in line with the in vitro results
in BMDMs (Figure 6). Both compounds significantly sup-
pressed LPS-induced Il6 and Ccl2 mRNA in peritoneal macro-
phages, confirming their anti-inflammatory potential on this
cell type in vivo.
Discussion
Our findings add new insights to the current paradigm of
NR3C1 functioning regarding classic and selective NR3C1
ligands and support the idea that mechanisms should be
revised or extended [23], depending on the cell types studied.
We observed in BMDM that only GCs (DEX) but not CpdA,
efficiently translocate NR3C1 to nuclei and consistently, that
Figure 5. Sqstm1 knockdown partially abolishes CpdA-induced suppression of Ccl2 and Il6 genes. (A) CCL2 and IL6 ELISA from the medium of BMDMs after 30 min 10
μM chloroquine (CQ) pretreatment and then 6 h treatment with 1 μM DEX, 10 μM CpdA, 100 ng/ml LPS and 10 μM CQ for 6 h. (N = 3). NI, non-induced. (B) qPCR
analysis of BMDMs treated with 1 μM DEX, 10 μM CpdA and 100 ng/ml LPS for 6 h. (C, D) Immunoblotting of BMDM treated with 1 μM DEX, 10 μM CpdA and 100 ng/
ml LPS for 15 min, 30 min or 6 h. ACTA1/actin served as a loading control. kDa, kilodaltons. (E) qPCR analysis of BMDMs treated with 1 μM DEX, 10 μM CpdA and
100 ng/ml LPS for 6 h after Sqstm1 and Nr3c1 were knocked down for 50 h. Gene expression levels were normalized to Ppia/cyclophilin and Gapdh using qbase+ .
Statistical analysis was done using one two-way ANOVA and Dunnett’s test (A, B, E) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, N = 4 or 5) .
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only GCs suppress LPS-induced inflammatory markers in a
NR3C1-dependent manner. We demonstrate here for the first
time that the selective NR3C1 modulator CpdA, characterized
as such in other cell models, can activate a subset of NFE2L2-
dependent genes, including Sqstm1, Hmox1, Nqo1 and
Txnrd1, both in basal and inflammatory states in human
and murine macrophages. In contrast, DEX treatment mainly
supports suppression of NFE2L2-dependent genes, which is in
line with recent findings in other cell types [39,40]. We con-
firmed that knockdown of Nr3c1 indeed abolished DEX-
induced repression of the ARE-containing Sqstm1 gene.
Although Nfe2l2 depletion lowered basal Sqstm1 mRNA
expression, a further DEX-mediated suppression was still
apparent. In contrast, Nfe2l2 knockdown substantially affected
the capacity of CpdA to induce Sqstm1 mRNA, indicating a
mechanism at least partially involving NFE2L2, rather than an
NR3C1-controlled mechanism.
In line with our novel findings of a predominant NFE2L2-
SQSTM1 involvement in CpdA’s action mechanism in macro-
phages, ChIP analysis demonstrated that only DEX treatment
recruits NR3C1, whereas CpdA treatment supports NFE2L2
recruitment to the Sqstm1 promoter. Still, mechanistic paral-
lels were also noted. For example, both DEX and CpdA
treatment decreased the binding of JUNB to the Sqstm1 pro-
moter. These data, together with an in silico analysis showing
that NFE2L2 and JUNB share the same motif, propose that
CpdA treatment may favor NFE2L2 over JUNB recruitment,
at least in BMDM.
CpdAwas demonstrated previously to suppress inflammatory
markers both at the mRNA and the protein level in vitro and in
vivo [9–13]. Anti-inflammatory properties of CpdAwere further
found to be also NR3C1-independent in bone marrow-derived
dendritic cells (BMDCs) [15]. In BMDCs, CpdA was shown to
impair TLR4 signaling. Also in BMDMs, we confirm that CpdA
may impair TLR4 signaling, at least at the level ofMAPK/ERK. In
the current study, we reveal that CpdA recruits NFE2L2 to
transcriptionally upregulate the Sqstm1 gene and subsequently
relies on the presence of functional SQSTM1 protein to mediate
anti-inflammatory gene expression at least in BMDMs. We
demonstrated that Sqstm1 silencing was indeed sufficient to
increase Il6 gene expression and to efficiently counteract the
anti-inflammatory properties of CpdA. This is in line with the
findings that SQSTM1 is a broad negative regulator of cytokine
expression in stimulated macrophages [41]. Our data also com-
plement a recent study showing that the upstream regulator
NFE2L2 itself can repress Il6 and Il1b genes by direct binding
to their promoters [42]. The involvement of SQSTM1 in the
regulation of different inflammatory proteins may be explained
by its role in autophagy as a cargo receptor. In support hereof,
Sqstm1 ablation prevents mitophagy and enhances NLRP3-
inflammasome activation [24] via a mechanism operating at
the protein level. In contrast and in addition, we discovered
that SQSTM1 is necessary for CpdA-mediated suppression of
Il6 and Ccl2 at the transcriptional level, and not dependent on
later stages of the autophagy process, because pharmacological
blocking with chloroquine failed to impair CpdA-induced proin-
flammatory gene suppression. The fact that CpdA strongly
induced SQSTM1 and increased overall protein ubiquitination,
could point to a role for the early stages of SQSTM1-ubiquiti-
nated protein aggregate formation in suppression of inflamma-
tion upon CpdA treatment. In support of this, Sergin et al.
demonstrated that in macrophages the sequestration of ubiqui-
tinated proteins by SQSTM1 appears to be a protective response
in minimizing inflammation [43]. Paradoxically, the
Figure 6. The regulation of a subset of stress response genes by CpdA and DEX in acutely inflamed peritoneal macrophages in vivo. qPCR analysis of FACS-sorted
peritoneal macrophages. Mice were treated i.p. with vehicle, 2 mg/kg DEX, 15 mg/kg CpdA and 1 mg/kg LPS for 6 h. Gene expression levels were normalized to Ppia/
cyclophilin and Gapdh using qbase+ . Statistical analysis was done using a Mann-Whitney test (*p < 0.05, **p < 0.01, N = 5–7). NI, non-induced.
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accumulation of SQSTM1 can also activate NFKB via its TRAF6
binding motif [44] and positively regulate chemokine expression
in keratinocytes [45], suggesting that the role of SQSTM1 is not
always purely anti-inflammatory but may depend on other con-
textual factors and/or the cell type.
Although DEX treatment led to a decrease in SQSTM1 at
the protein and mRNA levels, it still possessed potent anti-
inflammatory properties in BMDMs. Contributing DEX-trig-
gered NR3C1-dependent anti-inflammatory mechanisms
included NR3C1 binding to the promoters of Il6 and Il1b,
upregulation of anti-inflammatory genes (Dusp1, Tsc22d3)
and stabilization of NFKBIA/IκBα. In contrast, CpdA did
not exhibit these features. Instead it strongly induced
SQSTM1 as an alternative mechanism towards its anti-inflam-
matory properties. Despite this differential regulation of
SQSTM1 by DEX and CpdA, both compounds were able to
induce autophagy in BMDMs. However, CpdA-triggered
autophagy occurred earlier in time (LC3A/B-II upregulation)
and with a slightly different morphology (stronger vacuoliza-
tion). Intriguingly, except for the prominent transcriptional
upregulation of the autophagy receptor Sqstm1 by CpdA
treatment, the above-mentioned autophagy induction by
neither DEX nor CpdA was supported by a strong transcrip-
tional upregulation of key autophagy genes – Becn1, Atg5,
Atg7 and Atg10. Oppositely, CpdA rather decreased the level
of one of the upstream regulators of the autophagy machinery
at the protein level, ATG5. Perhaps an earlier described
physical interaction between SQSTM1 and ATG5 [46] could
explain degradation of ATG5 together with SQSTM1. The
interaction with upstream autophagy activators brings the
importance of autophagy receptor regulation to another
level. In addition to the observation that CpdA transcription-
ally induced autophagy receptors Sqstm1, Nbr1 and Calcoco2
in the inflamed BMDMs, we also showed that ablation of
SQSTM1 increased levels of Nbr1 and Calcoco2, but not of
Optn. This result may point to the existence of a possible
selective mechanism maintaining autophagy receptor balance
in macrophages.
Despite a vast interest in SQSTM1 due to its role in autophagy
and its associationwith a number of pathologies [47] there is little
information about the nuclear localization of SQSTM1 and its
role in the nuclear compartment. It was reported that SQSTM1
shuttles between the nucleus and cytoplasm and can be found in
nuclear promyelocytic leukemia bodies [48]. Using ChIP, we
tested the hypothesis that SQSTM1 might be present at the
promoters of the Il6 and Il1b genes in LPS-treated BMDM;
however, we failed to detect such recruitment to the transcrip-
tional machinery (data not shown), where NR3C1 and NFE2L2
recruitments were detected (Figure 3C).
In summary, we here reported on a novel mechanism by
which CpdA mitigates macrophage inflammation; i.e. not via
NR3C1 but via the transcriptional upregulation of the SQSTM1
protein (Figure 7). Our data imply that the search for safer anti-
inflammatory compounds might benefit from compounds that
Figure 7. The model of NFE2L2- and NR3C1-dependent transcriptional regulation of SQSTM1 following CpdA and DEX and its link to autophagy and inflammation in
macrophages. CpdA supports recruitment of NFE2L2 and a transcriptional, NR3C1-independent, upregulation of a subset of NFE2L2 pathway genes. One of those,
encoding SQSTM1, is involved in CpdA-mediated suppression of inflammation. Oppositely, NFE2L2 recruitment at Il6 and Il1b promoters results in the down-
regulation of these genes. DEX mediates NR3C1-dependent transcriptional suppression of Il6 and Il1b genes as a main driver of its potent anti-inflammatory
properties, yet is assisted by the upregulation of anti-inflammatory genes and the stabilization of NFKBIA/IκBα. The above-described transcriptional events result in a
release of the transcription factor JUNB. Both compounds are able to induce autophagy with slightly different characteristics. CpdA leads to stronger ubiquitination of
proteins at early time points, linking to aggregate-autophagy receptor binding [52]. Ub. cargo, ubiquitinated cargo; yellow lines depict activation or suppression by
CpdA; red lines depict activation or suppression by DEX; black and gray arrows depict movement and sequence of events.
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contain inflammatory processes not only via selective triggering
of NR3C1, but also via a direct transcriptional upregulation of
the autophagy receptor SQSTM1.
Materials and methods
Materials
Poly-L-lysine (P4832), dexamethasone/DEX (D4902-25MG),
rabbit anti-ACTA1 (A2066) and rabbit anti-SQSTM1 (P0067)
were purchased from Sigma. CpdA was synthesized according
to the protocol described previously [49]. Chloroquine (sc-
205,629), rabbit anti-NR3C1 (sc-8992x), mouse anti-LC3A/B
(sc-398,822), rabbit anti-NFE2L2 (sc-13,032), rabbit anti-
NFKBIA (C-21) and normal rabbit IgG (sc-2027) were from
Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-
coupled secondary anti-rabbit (111–035-144) and anti-mouse
(115–035-146) antibodies were purchased from Jackson
ImmunoResearch. Rabbit anti-JUNB (C37F9), rabbit anti-
ATG5 (2630), rabbit anti-p-MAPK/ERK (9101), mouse anti-
MAPK/ERK (L34F12), mouse anti-p-MAPK/p38 (L28B10)
and rabbit anti-MAPK/p38 (9212) were purchased from Cell
Signalling Technology. Rabbit anti-HMOX1 (SPA-896) anti-
bodies were from StressGen. Mouse anti-ubiquitin (VU-0101)
antibodies were purchased from LifeSensors. Protein A
Sepharose beads (17–5138-01) were from GE Healthcare Life
Sciences. RNAse A (740,505) was from Macherey-Nagel.
Proteinase K (19,131) was from Qiagen. LPS (tlrl-eklps) was
purchased from Invivogen.
Cell culture
Mouse bone marrow-derived macrophages were isolated from
8- to 12-week-old male wild-type C57BL/6 mice. Leg bones
were washed with 70% ethanol and twice with ice-cold, sterile
phosphate-buffered saline (PBS; Gibco, 14,190–094). After
washing, bones were gently smashed using a pestle in a
mortar containing 10 ml ice-cold, sterile PBS. Bone marrow
was filtered through a 70-μm cell strainer and centrifuged
(400 g, 7 min, 4°C). Cells were resuspended in 2 ml of RBC
osmotic lysis buffer (155 mM NH4Cl, 10 mM KHCO3,
0.1 mM EDTA, pH 7.3) for 2 min followed by washing with
PBS. After centrifugation under the same condition (400 g,
7 min, 4°C), cells were filtered again and seeded for 7 days
differentiation in DMEM (Gibco, 41,966–029) supplemented
with 10% fetal calf serum, 0.55% gentamycin and 50 ng/ml
recombinant CSF1/M-CSF (VIB Protein Service Facility,
L00810). The medium was refreshed every 2–3 days. Cells
were maintained in a 5% CO2 humidified atmosphere at 37°C.
Sample preparation and LC-MS/MS
Approximately 600,000 BMDM cells from each treatment
were pelleted by centrifugation (400 g, 5 min, 4°C) and washed
with cold PBS. The cell pellets were resuspended in lysis buffer
(8 M urea [Sigma, U5378] in 20 mM HEPES, pH 8.0) and
lysed using a microtip sonicator (15 W output, 3 bursts of 15
sec, cooling on ice in between bursts). The lysates were cleared
by centrifugation (20,000 g, 15 min at room temperature
[RT]). S-reduction and S-alkylation of the Cys residues was
performed by adding DTT (Sigma, D0632; final concentration
15 mM, 30 min at 55°C) and IAA (Sigma, 57,670; final con-
centration 30 mM, 15 min at RT in the dark), respectively. The
protein concentration was determined by the Bradford assay
and 250 µg of protein material was isolated from each sample,
which was then diluted 2-fold (to 4 M urea) and pre-digested
with 2.5 µg endoproteinase Lys-C (WAKO, 129–02541; 1:100
[w:w] ratio, 2 h at 37°C) before diluting further to 2 M urea for
overnight digestion with 5 µg trypsin (Promega, V5111; 1:50
[w:w] ratio, 37°C). The resulting peptide mixtures were pur-
ified on Sampli-Q C18 columns (Agilent, 5982–1111), dried
completely and then resuspended in 20 µL of loading solvent
A (0.1% TFA in water:acetonitrile, 2:98 [v:v]), from which 2 µL
was used to determine the peptide concentration (Lunatic,
Unchained Labs). An aliquot of the peptide material (3 µg)
from each sample was introduced into an LC-MS/MS system
through a tandem configured Ultimate 3000 RSLC nano LC
(Thermo Scientific, Germany) in-line connected to an LTQ-
Orbitrap Elite (Thermo Fisher Scientific, Germany). The sam-
ple mixture was first loaded on a trapping column (made in-
house, 100-µm internal diameter x 20-mm length, 5-µm beads
C18 Reprosil-HD, Dr. Maisch). After flushing from the trap-
ping column, the sample was loaded on a reverse-phase col-
umn (made in-house, 75-μm internal diameter x 400-mm
length, 1.9-µm beads C18 Reprosil-HD, Dr. Maisch).
Peptides were loaded with loading solvent A and were sepa-
rated with a non-linear gradient from 98% solvent A (0.1%
formic acid in water) to 56% solvent B (0.1% formic acid in
water:ACN 20:80 [v:v]) at a flow rate of 250 nl/min followed
by a 10 min wash reaching 99% solvent B. The mass spectro-
meter was operated in a data-dependent mode, positive ioni-
zation mode, automatically switching between MS and MS/MS
acquisition for the 20 most abundant peaks in a given MS
spectrum. The source voltage was 3.5 kV, and the capillary
temperature was 275°C. In the LTQ-Orbitrap Elite, full scan
MS spectra were acquired in the Orbitrap (m/z 300−2 000,
AGC target 3,000,000 ions, maximum ion injection time
100 ms) with a resolution of 60,000 (at 400 m/z). The 20
most intense ions fulfilling predefined selection criteria
(AGC target 5,000 ions, maximum ion injection time 20 ms,
spectrum data type: centroid, exclusion of unassigned and 1
positively charged precursors, dynamic exclusion time 20 sec)
were then isolated in the linear ion trap and fragmented in the
high-pressure cell of the ion trap. The CID collision energy
was set to 35 V and the polydimethylcyclosiloxane background
ion at 445.120028 Da was used for internal calibration (lock
mass). Column temperature was kept constant at 50°C.
LC-MS/MS data analysis
Data searching was done with the MaxQuant software (v
1.6.0.16) using the Andromeda search engine with default
search settings including a false-discovery rate (FDR) set at
1% on both the peptide and protein level. Spectra were
searched against the mouse proteins in the UniProt database
(September 2017 database release, www.uniprot.org). The
mass tolerance for precursor and fragment ions was set to
20 ppm and 4.5 ppm, respectively, during the main search.
2060 V. MYLKA ET AL.
Enzyme specificity was set to C-terminal of Arg and Lys
residues, even when they were followed by a Pro residue,
with a maximum of 2 missed cleavages. Variable modifica-
tions were set to oxidation of methionine residues and protein
N-terminal acetylation. A minimum of 1 peptide was required
for identification, and matching between runs was allowed
using a 2-min time window and a 20-min alignment window.
Proteins were quantified by the MaxLFQ algorithm integrated
in the software and a minimum ratio count of 2 unique or
razor peptides was required for quantification. Downstream
data analysis was performed with the Perseus software
(v.1.6.0.7) using the ProteinGroup.txt file from a MaxQuant
database search. Proteins that were only identified by site and
reversed database hits were removed as well as potential con-
taminants. The protein LFQ intensities were log2 transformed
to obtain a normal distribution, and the replicate samples
were grouped by their treatment. For each comparison the
concerning groups were isolated and filtered for at least 3
valid values in at least 1 group. The missing values were
input with values from the lower part of the normal log2
transformed LFQ distribution, representing the detection
limit. Multiple 2-sample t-tests were performed, each with a
permutation-based FDR of 0.05 and S0 of 0.1 for truncation
with a total of 1,000 randomizations. The results were visua-
lized as volcano plots.
In vivo experiments and FACS analysis
Experiments were approved by the animal ethics committee
of the Faculty of Medicine and Health Sciences at the
University of Ghent (code dossiers 14/84 and 17/13). Mice
were purchased at Charles River. Male 8- to 12-week-old
wild-type C57BL/6 mice were intraperitoneally injected with
vehicle, 2 mg/kg dexamethasone (DEX) or 15 mg/kg CpdA
in combination with 1 mg/kg LPS. Six h later, mice were
sacrificed and peritoneal cavities were lavaged with 5 mL
PBS containing 0.1 mM EDTA. All samples contaminated
with an exaggerated number of erythrocytes were excluded
from the analysis. To determine the cellular composition of
peritoneal lavage fluids, cells were stained with antibodies
against ADGRE1/F4/80 (eBioscience, 13–4801-85), MHC
class II (eBioscience, 47–5321-82), CD19 (eBioscience,
15–0193-83), CD3 (eBioscience, 15–0031-83), LY76/Ter119
(eBioscience, 15–5921-82), FCGR1/CD64 (Biolegend,
139,311), SIGLECF (BD Biosciences, 552,126), LY6G (BD
Biosciences, 551,460), ITGAM/CD11b (BD Biosciences,
560,455) and streptavidin (BD Biosciences, 563,260). Dead
cells were always excluded from the analysis using the fix-
able viability dye eFluor506 (eBioscience, 65–0866-18).
Acquisition of multicolor samples and cell sorting was
done on an Aria II flow cytometer (BD Biosciences).
Analysis and graphic output were performed with FlowJo
software (Tree Star).
ChIP
ChIP assays were performed as described previously [50]. In
brief, BMDM were plated on 15-cm dishes. Stimulation was
done for 1 h with ethanol, 1 μM DEX or 10 μM CpdA.
Proteins were cross-linked to DNA for 10 min using 1%
formaldehyde and the cross-linking reaction was stopped
by adding glycine to a final concentration of 0.125 mM.
Cells were scraped in ice-cold PBS, washed twice and lysed
with 500 μl of lysis buffer (0.1% SDS [Merck, 8,170,341,000],
1% Triton X-100 [Sigma, X100], 0.15 M NaCl, 1 mM EDTA,
20 mM Tris-HCl pH 8) supplemented with protease inhibi-
tor cocktail (Pierce, 88,265) and sonicated 30x (30s on/30s
off, high intensity) using a Bioruptor sonicator (Diagenode)
at 4°C. Insoluble material was removed by centrifugation
(20 min, 20,000 g, 4°C). For each immunoprecipitation,
100 μl of chromatin was diluted 4 times with incubation
buffer (0.15% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM
EDTA, 20 mM HEPES pH 7.4), mixed with 5 µg of anti-
bodies to NR3C1, NFE2L2, JUNB or normal IgG antibodies
and incubated for 2 h at 4°C with rotation. Protein A
Sepharose beads slurry (40 µl per each immunoprecipitation;
GE Healthcare Life Sciences, 17–5138-01) were washed twice
and blocked in incubation buffer with 1 μg/μl BSA (Sigma,
A8806; 2 h, 4°C with rotation). Diluted chromatin samples
were mixed with a protein A Sepharose solution and incu-
bated overnight at 4°C with rotation. The next day, beads
were washed twice in wash buffer 1 (0.1% SDS, 0.1% NaDOC
[Sigma, D6750], 1% Triton X-100, 0.15 M NaCl, 1 mM
EDTA, 20 mM HEPES pH 7,4), once in wash buffer 2
(0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl,
1 mM EDTA, 20 mM HEPES pH 7.4), once in buffer 3
(0.25 M LiCl, 0.5% NaDOC, 0.5% NP-40 [Calbiochem,
492,016], 1 mM EDTA, 20 mM HEPES pH 7.4) and twice
in wash buffer 4 (1 mM EDTA, 20 mM HEPES pH 7.4).
Protein-DNA complexes were eluted in 200 μl (1% SDS
+ 0.1 M NaHCO3) at room temperature and cross-links
were reversed at 65°C overnight by adding 8 μl of 5 M
NaCl, together with 8 μl of 0.5 mg/ml RNAse A and 10 μl
of 20 mg/ml Proteinase K. DNA was purified with a
QIAquick PCR purification kit (Qiagen, 28,106) according
to the user’s manual. Precipitated DNA was analyzed by
qPCR. Primer sequences used for ChIP-qPCR analysis are
listed in Table S1.
Gene silencing
siCtrl (D-001810–10-05), mouse ON-TARGET siSqstm1 (M-
047628–01-0005), siNfe2l2 (J-040766–05-0005) and siNr3c1
(L-045970–01-0005) were ordered from Dharmacon and
used at 28 nM final concentration. Genes were silenced for
50 h using the VIROMER Green kit (Lipocalyx, VG-01LB)
according to the manual.
qPCR and ChIP-qPCR
RNA was isolated with the RNeasy purification kit (Qiagen,
74,106) according to the user’s manual. cDNA was synthe-
sized with a PrimeScript kit (Takara, 6110B). qPCR was per-
formed using Light Cycler 480 SYBR Green I Master Mix
(Roche, 04887352001). The full primer list is provided in
Table S1. qPCR data were normalized and quantified relative
to the 2 most stable reference genes with qbase+ [51].
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Immunofluorescence
BMDM cells were seeded on poly-L-lysine coated µ-Slide 8
Well chambers (Ibidi, 80,826) and treated with EtOH, 1 μM
DEX, 10 μM CpdA and 100 ng/ml LPS. Cells were washed
with PBS and fixed with 4% paraformaldehyde for 15 min at
room temperature. After 3 washes with PBS (5 min each),
cells were permeabilized with ice-cold methanol for 20 min
followed by incubation with blocking buffer (4.5 mM
Na2HPO4, 15.5 mM NaH2PO4, 100 mM NaCl, 0.23% TX-
100, 10% donkey serum [Jackson ImmunoResearch,
017–000-121]). Cells were incubated overnight at 4°C with
rabbit anti-SQSTM1 (1:500), mouse anti-NR3C1 (1:500; Santa
Cruz Biotechnology, G-5) or rabbit anti-NFE2L2 (1:300).
After 3 washes with PBS, cells were stained with rabbit
Alexa Fluor 568 (Invitrogen, A10042) and mouse Alexa
Fluor 488 (Invitrogen, A21202) antibodies together with
260 nM DAPI for 45 min at room temperature. Cells were
washed 3 times in washing buffer (blocking buffer without
serum) and once with PBS. Mounting solution was added and
slides were analyzed on an Olympus microscope (IX81) with
Fluoview 1000 version 4.2 software.
Transmission electron microscopy
Cell cultures of mouse BMD macrophages were grown on
glass cover slips and fixed in 4% paraformaldehyde and
2.5% glutaraldehyde in 0.1 M NaCacodylate buffer, pH 7.2
for 4 h at room temperature followed by fixation overnight at
4°C. After washing, cells were subsequently dehydrated
through a graded ethanol series, including a bulk staining
with 1% uranyl acetate at the 50% ethanol step followed by
embedding in Spurr’s resin (EMS/Aurion, 14,300). Ultrathin
sections of a gold interference color were cut using an ultra-
microtome (Leica EM UC6), followed by a post-staining in a
Leica EM AC20 for 40 min in uranyl acetate at 20°C, and for
10 min in lead stain at 20°C. Sections were collected on
formvar-coated copper slot grids (Agar Scientific,
AGG2500C). Grids were viewed with a JEM 1400plus trans-
mission electron microscope (JEOL, Japan) operating at
60 kV.
Immunoblot analysis
Cells cultured in 6-well plates were solubilized in mRIPA
buffer (50 mM Tris, pH 8, 200 mM NaCl, 0.5% NaDOC,
0.05% SDS, 1% NP-40, 2 mM EDTA) together with pro-
tease inhibitor cocktail (Roche, 11,873,580,001), 2 mM NaF
and 1 mM Na3VO4. Total lysates were boiled 5 min at 95°C
with 5x Laemmli buffer (0.156 M Tris, pH 6.8, 5% SDS,
25% glycerol, 5% β-mercaptoethanol) and resolved by 10%
or 15% SDS-PAGE. Then transferred onto 0.45-µm nitro-
cellulose membranes (GE Healthcare, 10,600,016) and
incubated with Blocking buffer (Thermo Scientific,
37,538), diluted with TBS (50 mM Tris, pH 7.5, 150 mM
NaCl) in a 1:1 ratio. Subsequently, membranes were incu-
bated with antibodies to SQSTM1 (1:2000), LC3A/B
(1:1000), ACTA1 (1:4000), ATG5 (1:1000), HMOX1
(1:1000), p-MAPK/ERK and p-MAPK/p38 (1:1000),
MAPK/ERK and MAPK/p38 (1:2000), NFKBIA (1:1000),
and ubiquitin (1:2000) diluted in Blocking buffer-TBS con-
taining 0.1% Tween 20 (Sigma, P7949; TBS-T). After wash-
ing in TBS-T, chemiluminescent detection was performed
using HRP secondary antibodies (1:10,000; Jackson
ImmunoResearch, 111–035-144, 115–035-146) and a che-
miluminescent substrate kit (Thermo Scientific, 34,078).
Densitometric analysis of western blot results was per-
formed using ImageJ.
mRNA stability assay
BMDM cells were plated and treated with ethanol, 1 μM DEX
and 10 μM CpdA for 6 h, with or without the transcription
inhibitor actinomycin D (10 μg/ml; Life Technologies,
11,805,017). mRNA levels of Sqstm1 and Hmox1 were
detected by qPCR.
ELISA
CCL2 and IL6 ELISA was performed on media from BMDM
cells after 6 h induction with ethanol, 1 μM DEX or 10 μM
CpdA in combination with 100 ng/ml LPS and 10 μM chlor-
oquine (added 30 min prior to the induction with com-
pounds) by using the ELISA MAXTM Standard (BioLegend,
432,702, 430,502), according to the manual.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
software (version 7.02). Significant differences between
groups were evaluated using one-way (1 factor with more
than 2 groups) or two-way (2 factors) ANOVA with
Dunnett’s test for multiple comparison (recommended for
comparison treatments to solvent controls, marked as NI),
which was found to be appropriate as groups displayed a
normal distribution. Normality was tested with the
D’Agostino-Pearson normality test. For comparison of 2
groups, a two-tailed t-test was used. When variances across
groups were not equal, logarithmic transformation was
applied prior to statistical analysis with the following
back-transformation. In vivo experiments were analyzed
using the Mann-Whitney test. Values are expressed as
mean + SEM, and error bars were derived from biological
replicates rather than technical replicates. p < 0.05 was
considered statistically significant.
Abbreviations
BMDM bone marrow-derived macrophage
CCL2/MCP1 chemokine (C-C motif) ligand 2
CpdA compound A
DEX dexamethasone
DUSP1 dual specificity phosphatase 1
HMOX1 heme oxygenase 1
IL6 interleukin 6
MAP1LC3/LC3 microtubule-associated protein 1 light chain 3
NFE2L2/NRF2 nuclear factor, erythroid derived 2, like 2
NR3C1/GR nuclear receptor subfamily 3, group C, member 1
SQSTM1/p62 sequestosome 1
TSC22D3/GILZ TSC22 domain family, member 3
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